World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
47593
World Ranking
13393
National Ranking
397

Yuichiro Ohe publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Yuichiro Ohe sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 832 publications — 89th percentile

89% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Yuichiro Ohe D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Yuichiro Ohe sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 87 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Yuichiro Ohe is affiliated with the National Cancer Centre in Japan and has contributed extensively to research in the field of medicine, particularly focusing on pulmonary and respiratory medicine, oncology, and molecular biology. Their work spans multiple subfields including cancer research and surgery.

Their research covers a range of topics in oncology and respiratory medicine, emphasizing lung cancer treatments and mutations, cancer immunotherapy and biomarkers, and lung cancer diagnosis and treatment. Additional areas of focus include colorectal cancer treatments and studies, cancer genomics and diagnostics, and interstitial lung diseases and idiopathic pulmonary fibrosis.

Yuichiro Ohe has authored and co-authored papers in prominent scientific journals and medical periodicals. Some of the recent significant publications include:

  • Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer, 2020, New England Journal of Medicine
  • TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer, 2020, Annals of Oncology
  • Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial, 2022, The Lancet Oncology
  • First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial, 2021, Journal of Thoracic Oncology
  • The Development of a Skin Cancer Classification System for Pigmented Skin Lesions Using Deep Learning, 2020, Biomolecules

Collaborations have been an integral part of their research practice, with frequent co-authors including Hidehito Horinouchi, Tatsuya Yoshida, Noboru Yamamoto, Yasushi Goto, and Yusuke Okuma.

Yuichiro Ohe's publications frequently appear in several key academic venues, reflecting their active presence in the oncology and respiratory medicine research communities. These venues include:

  • Annals of Oncology
  • Journal of Clinical Oncology
  • Lung Cancer
  • Japanese Journal of Clinical Oncology
  • Journal of Thoracic Oncology

Overall, the scientist's contributions are situated mainly within the broad discipline of medicine, with a focus on lung cancer treatments and related biomedical research. Their work intersects clinical trials, therapeutic approaches, and molecular studies aimed at understanding and addressing cancer and respiratory diseases.

Best Publications

  • Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

    Tony S. Mok;Yi Long Wu;Sumitra Thongprasert;Chih Hsin Yang

  • Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

    Jean-Charles Soria;Yuichiro Ohe;Johan Vansteenkiste;Thanyanan Reungwetwattana

  • AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

    Pasi A. Jänne;James Chih-Hsin Yang;Dong Wan Kim;David Planchard

  • Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

    Suresh S Ramalingam;Johan Vansteenkiste;David Planchard;Byoung Chul Cho

  • Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer

    Toshimi Takano;Yuichiro Ohe;Hiromi Sakamoto;Koji Tsuta

  • Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan

    Y Ohe;Y Ohashi;K Kubota;T Tamura

  • CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

    Takashi Seto;Katsuyuki Kiura;Makoto Nishio;Kazuhiko Nakagawa

  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

    Alexander Drilon;Geoffrey R. Oxnard;Daniel S.W. Tan;Herbert H.F. Loong

  • Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.

    Suresh S. Ramalingam;James C.-H. Yang;Chee Khoon Lee;Takayasu Kurata

  • Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.

    Alexander Drilon;Alexander Drilon;Salvatore Siena;Rafal Dziadziuszko;Fabrice Barlesi

  • Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study

    S.S. Ramalingam;Y. Cheng;C. Zhou;Y. Ohe

  • TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

    G.R. Oxnard;J.C.-H. Yang;H. Yu;S.-W. Kim

  • Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial

    Kiyotaka Yoh;Takashi Seto;Miyako Satouchi;Makoto Nishio

  • Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.

    Seiji Yano;Tadaaki Yamada;Shinji Takeuchi;Keisei Tachibana

  • Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer

    Koichi Goto;Yukito Ichinose;Yuichiro Ohe;Nobuyuki Yamamoto

  • EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan

    Toshimi Takano;Tomoya Fukui;Yuichiro Ohe;Koji Tsuta

  • Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301)

    Shinji Atagi;Masaaki Kawahara;Akira Yokoyama;Hiroaki Okamoto

  • Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib

    Toshimi Takano;Yuichiro Ohe;Masahiko Kusumoto;Ukihide Tateishi

  • Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT).

    Morihito Okada;Takashi Kijima;Keisuke Aoe;Terufumi Kato

  • First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

    Luis G. Paz-Ares;Suresh S. Ramalingam;Tudor-Eliade Ciuleanu;Jong-Seok Lee

Frequent Co-Authors

Tomohide Tamura
Tomohide Tamura St. Luke's International Hospital
Nagahiro Saijo
Nagahiro Saijo AstraZeneca (United Kingdom)
Kazuhiko Nakagawa
Kazuhiko Nakagawa Kindai University
Yutaka Nishiwaki
Yutaka Nishiwaki Tokyo Medical University
Hiroaki Okamoto
Hiroaki Okamoto Jichi Medical University
Teruhiko Yoshida
Teruhiko Yoshida National Cancer Research Institute, UK
Kazuto Nishio
Kazuto Nishio Kindai University
Kanji Nagai
Kanji Nagai Kitasato University
Takashi Kohno
Takashi Kohno National Cancer Centre
Koji Tsuta
Koji Tsuta Kansai Medical University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always mean attending in-person classes. There are several related online degree options for those interested in growing their healthcare expertise from home. Many students begin by considering programs like the cheapest bsn programs online, which help prepare future nurses through flexible and affordable study.

If you’re aiming for an advanced nursing career, check out the cheapest fnp programs online and the cheapest dnp programs. These programs offer an accessible pathway to becoming a nurse practitioner or earning a doctoral degree in nursing—all via online learning.

For those interested in working behind the scenes in healthcare, getting certified in medical billing and coding is a practical option. Many wonder about medical coding certification cost and how to choose a program that suits both their budget and timeline.

Online degrees and certifications make it easier than ever to start or advance a career in medicine, while balancing other commitments.

Best Scientists Citing Yuichiro Ohe

Trending Scientists

Recently Published Articles